Cent Eur J Public Health 2022, 30(4):213-218 | DOI: 10.21101/cejph.a7300

Hepatitis B immunization data of patients living with HIV/AIDS: a multi-centre study

Servet Öztürk¹, Ayşe Serra Özel², Pinar Ergen³, Seniha Şenbayrak⁴, Canan Ağalar⁵

¹ Clinic of Infectious Diseases and Clinical Microbiology, Okan University Hospital, Istanbul, Turkey

² Clinic of Infectious Diseases and Clinical Microbiology, Umraniye Training and Research Hospital, University of Health Sciences, Istanbul, Turkey

³ Clinic of Infectious Diseases and Clinical Microbiology, Prof. Dr. Süleyman Yalçin Hospital, Medeniyet University, Istanbul, Turkey

⁴ Clinic of Infectious Diseases and Clinical Microbiology, Haydarpaşa Numune Training and Research Hospital, University of Health Sciences, Istanbul, Turkey

⁵ Clinic of Infectious Diseases and Clinical Microbiology, Medicana Ataşehir Hospital, Fenerbahçe University, Istanbul, Turkey

Objectives: Human immunodeficiency virus (HIV) and hepatitis B virus (HBV) are the two leading viruses that cause the greatest number of virus-related morbidities in the world. HIV/HBV coinfection is correlated with high morbidity and mortality. For this particular reason hepatitis B vaccination is crucial for people living with HIV.

Methods: Patients who are being followed-up for HIV/AIDS and who have received a hepatitis B vaccine in 4 HIV clinics over a 5-year time period have been studied. Our multi-centered, retrospective, cross-sectional and observational study investigates factors that affect hepatitis B vaccination immune response of individuals living with HIV. The patients have been studied for the parameters such as age, sex, CD4 count at the time of diagnosis or vaccination, HIV-RNA levels, comorbidities, vaccine dosage, success of immunization after vaccination, and the demographics of the patients who have and have not developed immunity.

Results: Of 645 patients that are being followed-up in our clinics, 158 received hepatitis B vaccine; 39 of these 158 patients have been excluded from the study because they did not fulfil the inclusion criteria. Finally, 119 patients were evaluated in the study, 17 of the patients (14.3%) were females and 102 (85.7%) were males. The median age was 41.11 ± 10.09 (min-max: 18-75). Twenty-three of the patients (19.3%) were at the stage of AIDS during diagnosis while 80.7% were at the stage of HIV infection. Ninety-one of the patients (76.5%) have been administered a single dose hepatitis B vaccine on the standard 0, 1st, 6th month vaccination schedule, whereas 23.5% were administered a double dose on the same vaccination schedule. When further evaluated to find whether the patient was able to develop sufficient immunity (anti-HBs ≥ 10), it was found that the immune response was statistically significantly higher in the patients whose CD4 count was greater than 200 at the time of the first diagnosis and vaccination (p = 0.05 and p = 0.001, respectively). The patients have also been evaluated according to the number of doses they received (1 vs. 2). The immune response of the patients who received two doses was statistically significantly higher (p = 0.041).

Conclusion: We can conclude that in the patients with CD4 count less than 200 at the time of their diagnosis and vaccination a high dose recombinant hepatitis B vaccine should definitely be administered as the normal dose and higher dose have similar side effect profiles and the higher dose provides greater immunity.

Klíčová slova: HIV/AIDS, hepatitis B vaccine, vaccination, Turkey

Vloženo: 25. leden 2022; Revidováno: 6. prosinec 2022; Přijato: 6. prosinec 2022; Zveřejněno: 31. prosinec 2022  Zobrazit citaci